Table 2.
Model 1 | Model 2 | Model 3 | Model 4 | |||||
---|---|---|---|---|---|---|---|---|
HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
Men | ||||||||
Levothyroxine treatment | 1.04 | 0.89–1.22 | 1.03 | 0.87–1.20 | 1.01 | 0.86–1.19 | 1.01 | 0.86–1.19 |
No treatment | Ref | Ref | Ref | Ref | ||||
Women | ||||||||
Levothyroxine treatment | 1.07 | 0.98–1.16 | 1.04 | 0.96–1.14 | 1.04 | 0.96–1.13 | 1.04 | 0.95–1.13 |
No treatment | Ref | Ref | Ref | Ref | ||||
Alla | ||||||||
Levothyroxine treatment | 1.07 | 0.99–1.15 | 1.04 | 0.97–1.12 | 1.03 | 0.96–1.12 | 1.03 | 0.96–1.11 |
No treatment | Ref | Ref | Ref | Ref |
Model 1 adjusted for age, Model 2 adjusted for age, educational level, immigrant status, marital status, and neighborhood deprivation, Model 3 Model 2 + comorbidities, Model 4 Model 3 + cardiovascular medications
aGender was added in the Model 2, Model 3, and Model 4